Funding for this research was provided by:
Shanghai Kaibao Pharmaceutical Co., Ltd (HX-G19-056)
Article History
Received: 21 April 2021
Accepted: 19 April 2022
First Online: 7 May 2022
Declarations
:
: The current study protocol (version 3.0) has been reviewed and approved by the Biomedical Ethics Committee of West China Hospital, Sichuan University (Chengdu, China) on 13 April 2020 (No.6). Written, informed consent to participate will be obtained from all participants.
: Not applicable.
: The authors declare that they have no competing interests.